Last updated on December 2018

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer


Brief description of study

Some HER-2 breast cancer patients do not respond or build resistance to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.

Clinical Study Identifier: NCT03248492

Contact Investigators or Research Sites near you

Start Over

Principal Investigator

Royal Surrey County Hospital
Guildford, United Kingdom
5.49miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.